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Immune suppression and disturbances of normal leukocyte populations are side effects attributed to many
antimalarial drugs and were concerns during a recent year-long placebo-controlled trial that compared daily
primaquine (0.5 mg of base per kg of body weight per day) with weekly chloroquine (300 mg of base one time
per week) for malaria prophylaxis. The study took place in Irian Jaya, Indonesia, from July 1994 to August
1995 and enrolled 129 Javanese men with normal glucose-6-phosphate dehydrogenase function. Tests for
lymphocyte function and subset composition were conducted blindly on a cross-section of subjects during weeks
10 (n 5 42) and 48 (n 5 72) of supervised prophylaxis. Lymphocyte function, measured as the proliferative
response of peripheral blood mononuclear cells to a panel of mitogens (pokeweed mitogen, phytohemagglutinin, and concanavalin A) and antigens (purified protein derivative of Mycobacterium tuberculosis and Clostridium tetani toxoid) and expressed as a stimulation index, allowed for statistical comparison between groups and
sampling times. The lymphocyte subset composition for each group and time point was based on flow cytometry
profiling, and the results were expressed as the mean percentages of CD3 (total T cells), CD19 (total B cells),
CD41 (T-helper and inducer cells), and CD81 (T suppressor and cytotoxic cells), CD3/CD161 CD56 (natural
killer cells), CD3/anti-HLA-DR (activated T cells) cells and the CD41/CD81 ratios. Lymphocyte stimulation
indices were statistically comparable among the placebo, primaquine, and chloroquine groups at both time
points, although the primaquine group was distinguished by having repeatedly greater proportions of subjects
with high (>3.0) stimulation indices. The lymphocyte subset profiles of these groups at both time points were
also similar and undistorted relative to those of healthy reference populations matched for age, sex, and
ethnicity. The results provide quantitative support for the safety of daily primaquine prophylaxis.
carboxy-1-methylpropylamino)-6-methoxyquinoline], has been
demonstrated by hematopoietic cells (11), and high doses have
induced leukocytosis, neutropenia, and granulocytopenia in
humans (5, 6, 8, 9). Evaluations of the short- and long-term
effects of primaquine prophylaxis on lymphocyte function and
subset profiles were therefore important additional safety issues. This report compares lymphocyte function and subset
profiles in primaquine, chloroquine, and placebo study groups
after moderate (10-week) and long-term (48-week) periods of
supervised chemoprophylaxis.

The 14-day regimen of primaquine for the radical cure and
terminal treatment of relapsing malaria has been in use for
nearly half a century, but owing to real or perceived issues of
toxicity, this drug has only recently been evaluated for use as a
malaria prophylactic (1, 12, 23). During a 12-month chemoprophylaxis trial in Irian Jaya, Indonesia, daily primaquine
provided better than 90% protection against falciparum and
vivax malaria, and no difference in the occurrence of physical
complaints or nonmalaria illness was seen between the primaquine, chloroquine, and placebo groups. With the exception of
asymptomatic methemoglobinemia, which was expected, no
evidence of primaquine toxicity was apparent in endpoint measures of renal and hepatic function (12). Nevertheless, immune
suppression and derangement of lymphocyte populations were
considered to be potentially insidious side effects that might
occur during extended chemoprophylaxis (4, 17, 19). Therapeutic levels of both chloroquine and primaquine in vitro have
been shown to depress mitogen-driven lymphocyte proliferation (14, 20). Chloroquine is concentrated in vivo by lymphocytes, where it is known to inhibit antigen processing (15, 18).
The in vivo effects of primaquine on lymphocyte function are
not known with certainty, but in vitro biotransformation of this
drug to its principal metabolite, carboxyprimaquine [or 8-(3-

MATERIALS AND METHODS
Study site and subjects. Details of the chemoprophylaxis study have been
published elsewhere (12). The study took place in Arso XI, northeastern Irian
Jaya, during the period between July 1993 and August 1994. This work was
conducted in accordance with U.S. Navy and Republic of Indonesia regulations
governing the protection of human subjects in medical research. American and
Indonesian committees for the protection of human subjects reviewed and approved the procedures followed in this research. After providing informed,
written consent, 129 adult male Javanese volunteers were tested to confirm that
they had normal glucose-6-phosphate dehydrogenase activity, curatively treated
with quinine-doxycycline-primaquine for any malaria infection, and randomized
to receive either daily primaquine (0.5 mg of base per kg of body weight daily; 30
mg daily for men weighing .55 kg), weekly chloroquine (300 mg of base one
time weekly), or a daily placebo over a 12-month period. Testing for lymphocyte
function and subset composition was delayed until week 10 of prophylaxis in
order to (i) allow the subjects to recover from preexisting malaria infections, (ii)
avoid the drug effects induced by the 14-day radical cure, and (iii) permit the
subjects to normalize to their prophylactic regimen. Laboratory testing was
performed by technicians blinded to the drug groups of the subjects. Subjects
reported no physical complaints or illness at the time of testing, and blood films
were negative for malaria parasites.

* Corresponding author. Mailing address: Malaria Program,
NAMRU-2 Box 3, APO AP 96520-8132. Phone: 62-21-421-4457. Fax:
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2737

2738

FRYAUFF ET AL.

Lymphocyte function. A random cross-sectional sample of volunteers (approximately 30%) was drawn from the study population to yield approximately equal
numbers of subjects receiving primaquine, chloroquine, or placebo for lymphocyte proliferation assays. Venous blood (20 ml) was collected during fasting into
heparinized tubes at the 10- and 48-week points of prophylaxis. After centrifugation, the plasma was removed and the buffy coat and top layer of erythrocytes
were transferred to an equal volume of RPMI wash medium (RPMI 1640
medium supplemented with 10 mM HEPES [N-2-hydroxyethylpiperazine-N9-2ethanesulfonic acid], 2% NaHCO3, 100 mg of gentamicin per ml, 2 mM glutamine). Peripheral blood mononuclear cells (PBMCs) were isolated by density
gradient centrifugation (Ficoll-Hypaque; Sigma Chemical Co., St. Louis, Mo.).
Washed PBMCs were counted with a hemocytometer, and the volume was
adjusted with cRPMI (RPMI medium supplemented with 10% pooled human
type AB serum) to achieve a final concentration of 106 PBMCs per ml. The
PBMCs (2 3 105 cells in 200 ml) were plated into each well of a round-bottom
microtiter plate (Costar, Cambridge, Mass.), and 10 ml of mitogen or antigen in
cRPMI was added to the well. The mitogen or antigen concentrations in the wells
at week 10 were as follows: pokeweed mitogen (PWM; Sigma), 2.5, 0.83, and 0.28
mg/ml; phytohemagglutinin A (PHA; Sigma), 10.0, 3.3, and 1.1 mg/ml; concanavalin A (ConA; Sigma), 12.5, 1.25, and 0.125 mg/ml; and purified protein
derivative of Mycobacterium tuberculosis (PPD; Connaught Laboratories Ltd.,
Willowdale, Ontario, Canada), 10.0, 3.3, and 1.1 mg/ml. The mitogen or antigen
concentrations in the wells at week 48 were as follows: PHA, 5.0 and 2.5 mg/ml;
PPD, 10.0 and 5.0 mg/ml; and Clostridium tetani toxoid (TET; Connaught), 10.0,
1.0, and 0.1 mg/ml. The PBMCs of the subjects were tested in quadruplicate
against each concentration of mitogen and antigen. cRPMI alone was added to
four to eight control wells containing PBMCs from each subject. The plates were
covered and were maintained at 378C in humidified air containing 5% CO2. On
day 6 each well was pulsed with 0.5 mCi of tritiated thymidine (Amersham
International plc, Buckinghamshire, United Kingdom) in cRPMI, and after an
additional 24 h of incubation the cells were harvested and washed and tritium
uptake was counted with a liquid scintillation counter (Top Count; Packard
Instrument Co., Meridien, Conn.). A stimulation index (SI) was determined, by
subject, for each mitogen and antigen concentration on the basis of the ratio of
the mean counts per minute of the stimulated wells to the mean counts per
minute of the unstimulated control wells. A significant proliferative response is
conventionally an SI of .2.0, but we arbitrarily applied the more stringent level
of an SI of $3.0 to define responders in this study.
Lymphocyte subset profiles. Differential counts of total leukocytes, percent
lymphocytes plus monocytes, percent granulocytes, and platelets were measured
by the quantitative buffy coat-complete blood count (QBC-CBC) centrifugal
method (Becton Dickinson Centrifugal Hematology System) from venous blood
at the baseline and at weeks 10 and 48 of prophylaxis. A venous blood sample of
3 ml was taken from the same subjects in the prophylaxis group subsets at the 10and 48-week points of prophylaxis and placed in EDTA-containing tubes (Becton Dickinson) for the enumeration of lymphocyte subsets by flow cytometry. All
reagents, procedures, equipment, and software used for flow cytometry were
from Becton Dickinson Immunocytometry Systems, San Jose, Calif. Respective
aliquots of blood in EDTA-containing tubes were incubated in the dark at room
temperature for 30 min with (i) a Simultest LeucoGATE (CD45/CD14 [antiHLe-1/Leu-M3]) negative control to set an exclusive lymphocyte gate free of
debris, monocytes, and granulocytes; (ii) Simultest Control g1/g2a (immunoglobulin G1 [IgG1], fluorescein isothiocyanate [FITC], and IgG2a phycoerythrin
[PE]) to set the fluorescence intensity and to measure nonspecific staining of the
sample; (iii) Simultest T- and B-cell test reagent (CD3/CD19 [anti-Leu-4 FITC/
anti-Leu-12 PE) for the percentages of total T cells and total B cells; (iv)
Simultest CD4/CD8 (Leu-3a/2a) for the percentage of CD41 T-helper and
inducer cells, the percentage of CD81 T-suppressor and cytotoxic cells, and the
CD41/CD81 ratio; (v) Simultest CD3/Anti-HLA-DR (Leu-4/anti-HLA-DR) for
the percentage of activated T cells; and (vi) Simultest CD3/CD161 CD56 (Leu4/11c119) for the percentage of natural killer cells. Staining was followed by
lysing of erythrocytes with fluorescence-activated cell sorter lysing solution,
washing to remove unbound antibody, and fixation in phosphate-buffered saline–1% formaldehyde. Negative control and sample aliquots for each subset of
interest were analyzed with a FACScan two-color flow cytometer equipped with
SimulSET software and interfaced with a desktop computer. Instrument calibration and quality control were performed daily by using CaliBRITE beads and
AutoCOMP software in accordance with the manufacturer’s recommendations.
Data for each sample and its negative controls were visually and automatically
inspected to determine quality. Samples with insufficient leukocytes or those
which did not meet all gating criteria were excluded from the analysis. Data for
samples which met all quality criteria proceeded through the software option for
percent lymphocyte conversion and were reported as appropriate estimates of
the true subset values.
Statistical analyses. SIs for the mitogen and antigen concentrations for the
subjects in the prophylaxis and placebo groups were log transformed and were
statistically compared by analysis of variance (ANOVA) if they were normally
distributed or by the Kruskal-Wallis nonparametric test if Bartlett’s test for
homogeneity of variance showed that the data were not normally distributed (2).
Statistical analyses between groups for each mitogen or antigen concentration in
the panel compared SIs for (i) the combined responder plus nonresponder
cohorts or (ii) the responder cohort only. A geometric mean SI (GMSI) and
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FIG. 1. Proportion of groups responding to mitogen or antigen after 10
weeks of malaria chemoprophylaxis. Responder subjects had an SI (mean counts
per minute for stimulated PBMCs/mean counts per minute for unstimulated
PBMCs) of $3. The mitogens or antigens were as follows: PWM tested at 2.5,
0.83, and 0.28 mg/ml; PHA tested at 10.0, 3.3, and 1.1 mg/ml; ConA tested at 12.5,
1.25, and 0.125 mg/ml; and PPD tested at 10.0, 3.3, and 1.1 mg/ml.

standard deviation were calculated for each group and for each mitogen or
antigen concentration. The proportion of responder subjects in each group was
compared by the chi-square or Fisher’s exact test. Differential counts of leukocytes at the baseline and at 10 and 48 weeks were compared by one-way
ANOVA, and selected groups were compared by the t test. The lymphocyte
subsets for each study subject were expressed as the percentage of the subject’s
total lymphocyte count. One-way ANOVA was applied to compare the counts
between the prophylaxis and placebo groups and against a larger reference
population (n 5 68) of healthy Indonesian men matched for age and JavaneseSundanese ethnicity.

RESULTS
Lymphocyte proliferative response. The frequency or proportion of responder subjects with SIs of .3.0 was repeatedly

FIG. 2. Proportions of groups responding to mitogen or antigen after 48
weeks of malaria chemoprophylaxis. Responder subjects had an SI (mean counts
per minute for stimulated PBMCs/mean counts per minute for unstimulated
PBMCs) of $3. The mitogens or antigens were as follows: PHA tested at 5.0 and
2.5 mg/ml; PPD tested at 10.0 5.0 mg/ml; and TET tested at 10.0, 1.0, and 0.1
mg/ml.
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TABLE 1. GMSIs of mitogen- or antigen-driven lymphocyte proliferation by combined prophylaxis group and responder cohort after 10
weeks of malaria chemoprophylaxisa
GMSI (SD) for the following prophylaxis group:
Stimulant and
concn

Placebo

Primaquine

Chloroquine

Combined

Responder

Combined

Responder

Combined

Responder

PWM
1:400
1:1,200
1:3,600

5.2 (7.5) (n 5 17)
6.7 (6.5) (n 5 17)
7.0 (6.6) (n 5 17)

28.8 (2.5) (n 5 9)
28.8 (2.5) (n 5 9)
28.8 (2.5) (n 5 9)

13.9 (4.2) (n 5 15)
14.9 (3.8) (n 5 15)
16.9 (3.6) (n 5 15)

25.5 (2.2) (n 5 12)
26.6 (2.0) (n 5 12)
29.1 (1.9) (n 5 12)

7.5 (10.1) (n 5 14)
7.6 (9.8) (n 5 14)
7.5 (8.8) (n 5 14)

37.9 (3.4) (n 5 9)
39.7 (3.0) (n 5 9)
36.0 (2.8) (n 5 9)

PHA
10.0 mg/ml
3.3 mg/ml
1.1 mg/ml

1.5 (4.6) (n 5 15)
1.6 (4.0) (n 5 16)
0.7 (2.8) (n 5 15)

10.5 (1.8) (n 5 5)
10.4 (1.7) (n 5 5)
5.9 (1.0) (n 5 2)

4.7 (2.7) (n 5 15)
3.1 (2.6) (n 5 15)
1.0 (2.2) (n 5 15)

8.3 (1.7) (n 5 10)
6.6 (1.7) (n 5 8)
4.8 (n 5 1)

2.4 (3.4) (n 5 12)
2.2 (3.1) (n 5 12)
0.9 (2.1) (n 5 12)

7.3 (1.4) (n 5 7)
6.7 (1.7) (n 5 7)
0

ConA
12.5 mg/ml
1.25 mg/ml
0.125 mg/ml

1.2 (3.2) (n 5 17)
3.3 (5.6) (n 5 17)
2.1 (5.2) (n 5 17)

7.9 (3.4) (n 5 3)
20.7 (2.6) (n 5 7)
21.3 (2.0) (n 5 5)

1.3 (2.4) (n 5 15)
7.6 (3.6) (n 5 15)
4.3 (4.2) (n 5 15)

5.0 (1.3) (n 5 3)
13.9 (2.3) (n 5 11)
12.0 (2.0) (n 5 9)

0.9 (2.6) (n 5 14)
3.8 (4.8) (n 5 14)
1.8 (3.5) (n 5 14)

4.1 (1.2) (n 5 2)
15.5 (1.9) (n 5 8)
8.7 (1.4) (n 5 6)

PPD
10.0 mg/ml
3.3 mg/ml
1.1 mg/ml

3.2 (5.8) (n 5 16)
2.7 (4.5) (n 5 17)
2.1 (3.8) (n 5 17)

19.3 (2.0) (n 5 7)
12.8 (2.7) (n 5 7)
13.0 (2.2) (n 5 5)

4.6 (3.3) (n 5 15)
3.6 (3.2) (n 5 15)
2.2 (2.4) (n 5 15)

9.0 (2.0) (n 5 10)
8.7 (1.8) (n 5 8)
5.1 (1.6) (n 5 6)

2.9 (5.0) (n 5 14)
1.6 (2.8) (n 5 14)
1.5 (2.7) (n 5 14)

17.6 (2.8) (n 5 6)
14.8 (1.6) (n 5 3)
8.6 (2.0) (n 5 4)

a

Combined refers to responders plus nonresponders, with responders referring to subjects with SIs of .3.0. The n values refer to the number of subjects.

more pronounced in the primaquine group during weeks 10
(Fig. 1) and 48 (Fig. 2) of prophylaxis. Individually, for each
mitogen or antigen concentration, these higher proportions
were not significantly different from those for the placebo or
chloroquine groups at either time point. Collectively, however,
there was statistical significance over the placebo group in the
occurrence of high responder frequencies in the primaquine
group for all three concentrations of a particular mitogen or
antigen (P 5 0.037) and in the occurrence of higher responder
frequencies for all four mitogens and antigens tested (P 5
0.012). The random probabilities of primaquine group responder frequencies exceeding those of the placebo group for
11 of 12 concentrations of mitogen or antigen tested during
week 10 (P 5 0.33311) and all 7 test concentrations during
week 48 (P 5 0.3337) were exceedingly small and therefore
indicative of an in vivo drug effect. GMSIs based on the responder and nonresponder subjects combined were, accord-

ingly, also consistently high for the primaquine group, but with
one exception (TET, 0.1 mg/ml; P 5 0.04) they were not significantly greater than those for the placebo or chloroquine
group for test concentrations of mitogen or antigen at either
sampling time (Tables 1 and 2). Statistical analyses which compared only the high responder (SI . 3.0) cohorts in the three
groups revealed that the GMSIs for the primaquine cohort
were not significantly different (P . 0.10) from those for the
placebo or chloroquine cohort at either the 10-week (Table 1)
or the 48-week (Table 2) time points. Analyses between responder cohorts at a less stringent cutoff (SI $ 2.0) but with a
greater power to detect differences also identified no significant differences (P . 0.07) between the groups (data not
shown). In contrast to the GMSIs for the primaquine group
derived from the values for the responders and nonresponders
combined, the GMSIs for the primaquine responder cohort
alone, calculated at low (SI . 2.0) and high (SI . 3.0; Table 1)

TABLE 2. GMSIs of mitogen- or antigen-driven lymphocyte proliferation by combined prophylaxis group and responder cohort after 48
weeks of malaria chemoprophylaxisa
Stimulant
and
concn
(mg/ml)

GMSI (SD) for the following prophylaxis group:
Placebo

Primaquine

Chloroquine

Combined

Responder

Combined

Responder

Combined

Responder

PHA
5.0
2.5

32.1 (2.3) (n 5 21)
9.2 (7.2) (n 5 21)

36.9 (1.8) (n 5 18)
19.9 (1.6) (n 5 16)

29.0 (2.9) (n 5 30)
14.3 (3.7) (n 5 30)

31.4 (2.7) (n 5 29)
21.0 (1.9) (n 5 26)

18.0 (6.5) (n 5 21)
13.6 (2.9) (n 5 21)

38.0 (2.6) (n 5 17)
18.5 (2.2) (n 5 17)

PPD
10.0
5.0

6.6 (3.0) (n 5 21)
4.9 (5.3) (n 5 21)

10.9 (2.1) (n 5 14)
10.9 (2.0) (n 5 14)

7.3 (2.6) (n 5 30)
7.7 (2.2) (n 5 30)

9.4 (1.9) (n 5 26)
8.9 (2.0) (n 5 26)

5.5 (3.5) (n 5 21)
6.5 (2.7) (n 5 21)

11.4 (2.3) (n 5 14)
10.9 (2.5) (n 5 12)

TET
10.0
1.0
0.1

1.3 (1.9) (n 5 21)
0.9 (1.7) (n 5 21)
1.3 (1.7) (n 5 21)

3.8 (1.1) (n 5 2)
0
3.9 (1.4) (n 5 2)

2.2 (2.6) (n 5 30)
1.4 (2.4) (n 5 30)
1.8 (2.5) (n 5 30)

8.4 (1.9) (n 5 8)
7.4 (1.4) (n 5 5)
5.8 (2.0) (n 5 8)

1.9 (2.4) (n 5 21)
0.9 (2.5) (n 5 21)
1.0 (2.3) (n 5 21)

7.1 (1.9) (n 5 5)
15.9 (n 5 1)
17.5 (n 5 1)

a

See footnote a of Table 1.

2740

FRYAUFF ET AL.

ANTIMICROB. AGENTS CHEMOTHER.

TABLE 3. Comparison of hematologic parameters in prophylaxis groups at baseline versus week 48 of chemoprophylaxisa
Percent

Platelet count
(109/liter)

Treatment group
and time periodb

Leukocyte count
(109/liter)

Granulocytes

Lymphocytes plus
monocytes

Primaquine
Pre (n 5 30)
Post (n 5 23)

7.2 6 2.1
7.3 6 2.2

61.2 6 10.3
52.2 6 11.2c

40.2 6 13.9
47.8 6 11.8c

283.5 6 76.7
281.5 6 100.4

Chloroquine
Pre (n 5 29)
Post (n 5 17)

7.7 6 2.0
7.3 6 2.2

62.6 6 8.1
56.1 6 10.2c

37.4 6 8.1
44.5 6 9.1c

261.2 6 97.5
274.8 6 87.9

Normal range

4.3–10.0

42–72

40–50

140–400

a
b
c

Values are means 6 1 standard deviation.
Pre, baseline; Post, week 48.
Significantly different (P , 0.05; unpaired comparison by t test).

response cutoff levels, were consistently below those for the
placebo cohort during week 10 of prophylaxis. Responder cohort GMSIs for all PHA and PPD concentrations during week
48 were comparable for the three groups (Table 2). There were
insufficient subjects with SIs of .3.0 for statistical comparison
of the responses of the cohorts to tetanus antigen during week
48, but at the less stringent level of an SI of .2.0, GMSIs for
the primaquine cohort were not significantly different from
those for the placebo or the chloroquine cohort (P . 0.15; data
not shown). No subject recollected having received a tetanus
immunization, but the disproportionately high SIs against low
tetanus concentrations registered by one subject in the chloroquine group may reflect a recent vaccination (Table 2). The
uptake of tritiated thymidine by unstimulated control cells for
the primaquine group (271 cpm [GM]; 95% confidence interval, 192 to 382 cpm) was significantly greater (P 5 0.01) than
that for placebo controls (129 cpm [GM]; 95% confidence
interval, 110 to 153 cpm) at week 10, but the uptakes for the
groups were comparable (P 5 0.86) at week 48.
Lymphocyte subset composition. Comparison between differential counts for both the primaquine and chloroquine
groups at the baseline and at week 48 identified significant
increases in the percentage of lymphocytes and monocytes at
week 48 over that at the baseline and significant reductions in
the percentage of granulocytes compared with that at the baseline. These changes did not fall outside the normal range, and
the baseline values may have been abnormally skewed by malaria infections at the time of enrollment (Table 3). The mean
leukocyte counts at week 48 were highest in the primaquine
group, but they were not significantly different (P 5 0.23; data
not shown) from those in the other groups. More-definitive
measures of the effect of prophylaxis on lymphocyte populations are profiled in Tables 4 and 5. The data in Tables 4 and
5 indicate that the mean percentages of total T cells, total B

cells, CD41 T cells, CD81 T cells, natural killer cells, and
activated T cells and the mean CD41/CD81 ratios were comparable among the placebo, primaquine, and chloroquine
groups at both time points. No significant differences were
identified between the groups within a time point or between
times within a prophylaxis group. The values obtained for the
prophylaxis groups all fell within the normal ranges derived by
profiling a larger reference sample of subjects matched to the
study subjects for age, sex, and ethnicity.
DISCUSSION
Lymphoproliferative responses to a panel of mitogens and
antigens were comparable among placebo, primaquine, and
chloroquine groups during weeks 10 and 48 of a malaria chemoprophylaxis trial and yielded no evidence of drug-induced
immune suppression. The lymphocyte subset profiles for these
groups at both time points were also similar to one another and
were undistorted relative to the profiles for a healthy reference
population matched for age, sex, and ethnicity.
The absence of evidence linking chloroquine prophylaxis
with lymphocyte disturbance was not surprising. Previous studies have documented only a reduced in vitro response to mitogenic stimulation by lymphocytes from patients undergoing
prolonged high-dose daily chloroquine treatment (250 mg/day)
for rheumatoid arthritis or by normal lymphocytes preincubated with high concentrations of the unmetabolized drug (14,
18).
The negative results for primaquine are similarly unspectacular but are ideal from the standpoint of its potential toxicity.
Even though primaquine has long been used for the treatment
of relapsing malaria, its pharmacology, metabolism, and mode
of action remain poorly understood (7, 21). It has been shown
that at least 11 metabolites can be formed in mammalian

TABLE 4. Lymphocyte subset composition among test groups after 10 weeks of chemoprophylaxis
% of total lymphocyte count (mean 6 1 SD)
Treatment group

CD3
(total T cells)

CD19
(total B cells)

CD41 T
cells

CD81 T
cells

Natural
killer cells

CD3/anti-HLA-DR
(activated T cells)

Placebo (n 5 17)
Primaquine (n 5 15)
Chloroquine (n 5 14)
Reference (n 5 68)a

65.1 6 9.0
71.1 6 7.6
69.4 6 11.5
61.0 6 10.3

13.9 6 4.3
12.3 6 3.7
13.3 6 4.2
13.2 6 5.0

34.5 6 6.1
33.4 6 5.2
33.2 6 7.2
30.2 6 7.4

38.9 6 5.2
37.3 6 6.1
39.3 6 8.8
43.0 6 8.0

21.2 6 8.7
17.3 6 8.9
23.7 6 15.4
26.6 6 11.2

16.2 6 8.7
14.9 6 7.6
21.4 6 10.2
21.0 6 6.4

a

Healthy Indonesian men of Javanese-Sundanese ethnicity.

CD41/CD81
ratio

0.91 6 0.22
0.94 6 0.23
0.88 6 0.24
0.75 6 0.33
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TABLE 5. Lymphocyte subset composition among test groups after 48 weeks of chemoprophylaxis
% of total lymphocyte count (mean 6 1 SD)
Treatment group

Placebo (n 5 15)
Primaquine (n 5 27)
Chloroquine (n 5 9)
Reference (n 5 68)a
a

CD3
(total T cells)

CD19
(total B cells)

CD41 T
cells

CD81 T
cells

Natural
killer cells

CD3/anti-HLA-DR
(activated T cells)

70.2 6 8.1
69.8 6 9.1
68.6 6 7.2
61.0 6 10.3

14.7 6 5.8
12.8 6 4.0
13.4 6 5.6
13.2 6 5.0

36.2 6 8.7
36.6 6 6.0
35.4 6 4.8
30.2 6 7.4

38.9 6 8.8
39.8 6 7.9
41.8 6 5.3
43.0 6 8.0

22.2 6 11.3
26.3 6 14.1
23.6 6 14.8
26.6 6 11.2

20.5 6 12.7
22.6 6 7.4
19.0 6 4.6
21.0 6 6.4

CD41/CD81
ratio

1.04 6 0.51
0.99 6 0.33
0.91 6 0.22
0.75 6 0.33

Healthy Indonesian men of Javanese-Sundanese ethnicity.

systems and that some have potent antimalaria activity and a
capacity to induce hemolysis and methemoglobinemia (21).
Carboxyprimaquine, the principal metabolite formed in humans, differs markedly from the parent compound in that it
attains higher concentrations in plasma (16) and is eliminated
more slowly (22). By virtue of these kinetics, progressive metabolite accumulation in tissue or plasma occurs when the drug
is used in a daily or alternate-day prophylactic regimen. The
general uncertainty that surrounds primaquine metabolite
function and toxicity provided the rationale for our efforts to
monitor subjects for subtle evidence of chronic immune suppression and lymphocyte imbalance.
There were repeatedly higher proportions of responder subjects and greater combined (responder plus nonresponder)
indices of lymphocyte proliferation in the primaquine group
during both time points. However, the proportions and indices
attained were not significantly greater than those for the placebo or chloroquine group. SIs derived from just the responder
cohorts of each group during week 10 of prophylaxis were also
not significantly different, but the indices for the primaquine
group responders were consistently below those for the placebo group. These outcomes appear to conflict and challenge
a simple interpretation of the in vivo effect of primaquine on
the basis of limited in vitro results. Relative to the placebo
group, the reverse trend from consistently high GMSIs for the
entire primaquine group to low GMSIs for its responder cohorts may have arisen partially and artificially from the effects
of unequal sample size reductions (reductions of 47 to 70% for
the placebo and chloroquine groups versus reductions of 20 to
40% for the primaquine group) on the GMs calculated for the
responder cohorts. An alternative or contributory explanation
may be that the actual drug effect in the primaquine group
manifested as a broadened but moderated enhancement of
mitogen- and antigen-stimulated lymphocyte proliferation.
Our results are in contrast to an earlier published finding
obtained with normal human lymphocytes preincubated in a
therapeutic concentration of primaquine (20). The in vitro
immunosuppressive effect that had been observed in that study
has been a widely cited aspect of primaquine toxicity (3, 6, 7,
13) and one that has possibly contributed to a long-standing
reluctance to consider the prophylactic value of this drug. Our
current methodology, which used lymphocytes chronically exposed in vivo to primaquine and its accumulated metabolites,
was intended to reflect more accurately the effect of prolonged
daily drug use upon lymphocyte function. Despite the improvement, our assays measured the responses of cells that had been
removed from exposure and placed into an entirely different
and metabolite-free environment. To gain a more realistic
picture of the effect of primaquine, we have begun studying the
mitogen-driven proliferative responses of unexposed and
chronically exposed PBMCs incubated in autologous serum
containing the naturally produced metabolites.
Normal therapeutic regimens with primaquine are reported

to induce mild disturbances in leukocyte populations (5, 6, 8,
9), and comparison within the primaquine group at the 52week endpoint of prophylaxis did measure a significant increase in the proportion of lymphocytes and monocytes and a
decrease in the proportion of granulocytes compared with the
proportions at the baseline. Notably, however, the same
changes occurred in the chloroquine group, and endpoint
means for both groups fell within the normal ranges. Comparative profiling of lymphocyte subsets in the chloroquine and
primaquine prophylaxis groups against those of either their
companion placebo group or a larger ethnically similar reference population did not yield evidence of a disturbance. The
mean percentages of total T cells, CD41 T cells, and CD81 T
cells and the CD41/CD81 ratios at both time points for each
of the three test groups were also comparable to the reference
values derived from a population of healthy adult Caucasians
(10). However, drug-induced changes in CD41 and/or CD81
cells, not reflected in absolute counts or subset percentages,
may have occurred and may have subsequently altered the
regulation of the proliferative response.
In summary, repeated testing for lymphocyte function and
subset composition during a year-long chemoprophylaxis trial
produced no evidence of suppression or disturbance induced
by moderate or long-term daily primaquine or weekly chloroquine regimens. While these results appear to provide a measure of safety assurance for the use of primaquine, they are
more appropriately intended to serve as a stimulus to further
study this drug.
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